ALNY Alnylam PharmaceuticalsWatchlist
About Alnylam Pharmaceuticals Company
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
US Weekly Movers & Shakers: Nov 20-Nov 24
Here are the top 10 gainers and losers of the week.
Insiders At Alnylam Pharmaceuticals Sold US$5.6m In Stock, Alluding To Potential Weakness
The fact that multiple Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowing wh
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $395 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $395 price target.
In reaction to earnings/guidance:
• $Aehr Test Systems(AEHR.US)$ +11.1% (also releases two new enhancements for its FOX-P family of wafer level test and burn-in systems)
• $Tilray Brands(TLRY.US)$ +5.1%
• $Payoneer Global(PAYO.US)$ +8.1% (to join SaP SmallCap 600)
• $Atlas(ATCO.US)$ +6.8% (continues negotiations with Poseidon Acquisition; parties have made meaningful progress on potential transactio...
• $AutoZone(AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $Chewy(CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $National Vision(EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $Fresenius Medical Care(FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $Gitlab(GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...